TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Gt Biopharma
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma reported progress on its Phase 1 clinical trial for GTB-3650, a TriKE® therapy targeting CD33-expressing hematologic malignancies, with successful advancement to Cohort 4 and no observed safety issues. The company plans to provide a trial update in Q1 2026 and anticipates submitting an IND for GTB-5550 in late December 2025.

Insights
GTBP   positive

Positive trial progression, no safety concerns, continued research advancement, and planned IND submission indicate promising development of therapeutic platform